{
  "ticker": "LEGN",
  "company_name": "Legend Biotech Corporation",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03674463",
      "title": "LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "Refractory or Relapsed Multiple Myeloma",
      "start_date": "2018-07-26",
      "completion_date": "2020-12-31",
      "enrollment": 0,
      "sponsor": "Second Affiliated Hospital of Xi'an Jiaotong University"
    },
    {
      "nct_id": "NCT04712864",
      "title": "Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent, Peripheral T-Cell Lymphoma Recurrent",
      "start_date": "2021-09-13",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Legend Biotech USA Inc"
    },
    {
      "nct_id": "NCT06472479",
      "title": "LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma",
      "status": "NOT_YET_RECRUITING",
      "phase": "NA",
      "condition": "Relapsed/Refractory Multiple Myeloma",
      "start_date": "2024-07-01",
      "completion_date": "2029-10-12",
      "enrollment": 0,
      "sponsor": "The First Affiliated Hospital with Nanjing Medical University"
    },
    {
      "nct_id": "NCT03758417",
      "title": "A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Multiple Myeloma",
      "start_date": "2019-01-23",
      "completion_date": "2025-10-20",
      "enrollment": 0,
      "sponsor": "Nanjing Legend Biotech Co."
    },
    {
      "nct_id": "NCT05498545",
      "title": "Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory Multiple Myeloma",
      "start_date": "2022-09",
      "completion_date": "2027-03",
      "enrollment": 0,
      "sponsor": "Second Affiliated Hospital of Xi'an Jiaotong University"
    },
    {
      "nct_id": "NCT03672253",
      "title": "CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression",
      "start_date": "2018-07-26",
      "completion_date": "2020-12-31",
      "enrollment": 0,
      "sponsor": "Second Affiliated Hospital of Xi'an Jiaotong University"
    },
    {
      "nct_id": "NCT03090659",
      "title": "LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma",
      "status": "UNKNOWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Refractory or Relapsed Multiple Myeloma",
      "start_date": "2015-10-02",
      "completion_date": "2023-12-31",
      "enrollment": 0,
      "sponsor": "Nanjing Legend Biotech Co."
    },
    {
      "nct_id": "NCT07095075",
      "title": "A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases",
      "status": "RECRUITING",
      "phase": "EARLY_PHASE1",
      "condition": "Relapsed/Refractory Autoimmune Diseases",
      "start_date": "2025-10-14",
      "completion_date": "2029-12-31",
      "enrollment": 0,
      "sponsor": "Nanjing Legend Biotech Co."
    },
    {
      "nct_id": "NCT05539430",
      "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer",
      "start_date": "2023-04-18",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Legend Biotech USA Inc"
    },
    {
      "nct_id": "NCT07002112",
      "title": "The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory B-cell Malignancies",
      "start_date": "2025-05-23",
      "completion_date": "2029-06-30",
      "enrollment": 0,
      "sponsor": "The First Affiliated Hospital with Nanjing Medical University"
    }
  ],
  "summary": {
    "total_trials": 37,
    "by_phase": {
      "PHASE1": 26,
      "NA": 3,
      "PHASE2": 1,
      "PHASE1, PHASE2": 1,
      "EARLY_PHASE1": 5,
      "": 1
    },
    "by_status": {
      "UNKNOWN": 6,
      "NOT_YET_RECRUITING": 3,
      "TERMINATED": 12,
      "RECRUITING": 12,
      "ACTIVE_NOT_RECRUITING": 1,
      "COMPLETED": 1,
      "WITHDRAWN": 2
    },
    "active_trials": 13,
    "completed_trials": 1,
    "conditions": [
      "Acute Leukemia, Acute Leukemia in Relapse, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemia",
      "Acute Lymphocytic Leukemia",
      "Acute Myeloid Leukemia",
      "Advanced Gastrointestinal Tumors",
      "B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory",
      "B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory",
      "Epithelial Ovarian Cancer",
      "Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer",
      "Gastric Cancer, Pancreatic Ductal Adenocarcinoma",
      "Healthy Subject",
      "Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma",
      "Lymphoma, B-Cell",
      "Multiple Myeloma",
      "Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression",
      "Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis",
      "Refractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia",
      "Refractory or Relapsed Multiple Myeloma",
      "Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma",
      "Relapsed and Refractory B-cell Non-Hodgkin Lymphoma",
      "Relapsed/Refractory Autoimmune Diseases",
      "Relapsed/Refractory B-cell Malignancies",
      "Relapsed/Refractory Multiple Myeloma",
      "Relapsed/Refractory Multiple Myeloma(MM)",
      "Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung",
      "Solid Tumors, Adult",
      "Systemic Lupus Erythematosus (SLE)",
      "Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)",
      "T Cell Lymphoma, T-cell Leukemia",
      "T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent, Peripheral T-Cell Lymphoma Recurrent"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:37.815728",
    "search_query": "Legend Biotech Corporation",
    "url": "https://clinicaltrials.gov/search?term=Legend+Biotech+Corporation"
  }
}